Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On December 31, 2014, Non-Executive Directors received allocations of notional Ordinary Shares and American Depositary Shares (ADSs) for the service period of October 1, 2014, to December 31, 2014. The allocation prices were set at £13.84 per Ordinary Share and $42.91 per ADS. These allocations were formally notified to the Company and Directors on January 5, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Date: Notional shares were allocated on December 31, 2014.
- Share Prices: Ordinary Shares were valued at £13.84; ADSs were valued at $42.91.
- Beneficiaries: Allocations were made to Non-Executive Directors including Sir Christopher Gent, Professor Sir Roy Anderson, and others.
- Notification Timing: The transaction was reported to the SEC on January 5, 2015.